Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
    • Transkriptioner
  • InderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Bolag under bevakning
    • Teamet
Regulatoriskt pressmeddelande

Boule Diagnostics appoints Michael af Winklerfelt as new CFO

Boule Diagnostics
Ladda ner börsmeddelandet

Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals, medical technology, and industrial sectors. He has served as CFO in several listed companies, overseeing finance, IT, HR, and investor relations. Michael has successfully led capital raisings, IPO processes, and strategic restructurings, strengthening Boule’s position and future opportunities. Previous roles include CFO at Fresenius Kabi Sweden AB, XSpray Pharma AB, Prostatype Genomics AB, and Oasmia AB, as well as senior finance positions within the Atlas Copco Group. He holds an MBA from Emory University and an MSc from the Stockholm School of Economics.

“We are delighted to welcome Michael as Boule’s new CFO. His strong financial expertise and broad experience across commercial and operational areas will be crucial in driving Boule’s global growth, improving profitability, and delivering innovation in decentralized blood diagnostics,” says Torben Nielsen, President and CEO.

Current CFO Holger Lembrér will remain in his role until Michael af Winklerfelt assumes the position in February 2026.

Contacts
Torben Nielsen, CEO and Group President, torben.nielsen@boule.com, phone +46 (0)70-558 51 05

About Us
Boule Diagnostics AB (publ) is a global company consisting of two business segments, Diagnostics and OEM CDS. Diagnostics is specialized in near-patient, decentralized diagnostic solutions for human and veterinary applications, serving hospitals, clinics, laboratories. OEM CDS develops and delivers reliable reagent, blood controls and calibrators tailored for diagnostic companies worldwide.
With operations in Sweden, the United States, Mexico, and Russia, and a global distribution network spanning more than 100 countries, Boule combines a resilient business model with strong positions in key growth markets. In 2024, Boule reported net sales of SEK 558 million and has about 200 employees worldwide. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com

This information is information that Boule Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-30 08:30 CET.

Attachments
Boule Diagnostics appoints Michael af Winklerfelt as new CFO

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.